A preclinical ¹⁸⁸Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49

References

• Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005; 11:7879 - 7885
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005; 11:1250 - 1255
   PubMed Web of Science ®Google Scholar
• Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003; 101:2340 - 2348
   PubMed Web of Science ®Google Scholar
• Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, et al. Comparison of immunoscintigraphy, efficacy and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003; 44:437 - 445
   PubMed Web of Science ®Google Scholar
• Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 1996; 37:967 - 971
   PubMed Web of Science ®Google Scholar
• Liu G, Mang'era K, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using 99mTc-labeled morpholino, a DNA analog. J Nucl Med 2002; 43:384 - 391
   PubMed Web of Science ®Google Scholar
• Liu G, Zhang S, He J, Liu N, Gupta S, Rusckowski M, et al. The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice. Q J Nucl Med 2002; 46:233 - 243
   PubMedGoogle Scholar
• Liu G, Liu C, Zhang S, He J, Liu N, Gupta S, et al. Investigations of 99mTc morpholino pretargeting in mice. Nucl Med Commun 2003; 24:697 - 705
   PubMed Web of Science ®Google Scholar
• Liu G, He J, Dou S, Gupta S, Vanderheyden JL, Rusckowski M, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging 2004; 31:417 - 424
   PubMed Web of Science ®Google Scholar
• Liu G, Dou S, Mardirossian G, He J, Zhang S, Liu X, et al. Successful radiotherapy of tumor in pretargeted mice by 188Re radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analog. Clin Can Res 2006; 12:4958 - 4964
   PubMed Web of Science ®Google Scholar
• Liu G, Dou S, Rusckowski M, Hnatowich DJ. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther 2008; 7:1025 - 1032
   PubMed Web of Science ®Google Scholar
• Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, et al. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging 2010; 54:333 - 340
   PubMed Web of Science ®Google Scholar
• Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP. Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med 2005; 46:121 - 129
   PubMed Web of Science ®Google Scholar
• Dadachova E, Moadel T, Schweitzer AD, Bryan RA, Zhang T, Mints L, et al. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm 2006; 21:117 - 129
   PubMed Web of Science ®Google Scholar
• García-Garayoa E, Bläuenstein P, Blanc A, Maes V, Tourwé D, Schubiger PA. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2009; 36:37 - 47
   PubMed Web of Science ®Google Scholar
• Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J Nucl Med 1998; 39:34 - 42
   PubMed Web of Science ®Google Scholar
• Dadachova E, Moadel T, Schweitzer AD, Bryan RA, Zhang T, Mints L, et al. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm 2006; 21:117 - 129
   PubMed Web of Science ®Google Scholar
• Dadachova E, Revskaya E, Sesay MA, Damania H, Boucher R, Sellers RS, et al. Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther 2008; 7:1116 - 1127
   PubMed Web of Science ®Google Scholar
• Jia ZY, Deng HF, Pu MF, Luo SZ. Rhenium-188 labelled meso-tetrakis[3,4-bis(carboxymethyleneoxy) phenyl] porphyrin for targeted radiotherapy: preliminary biological evaluation in mice. Eur J Nucl Med Mol Imaging 2008; 35:734 - 742
   PubMed Web of Science ®Google Scholar
• Zamora PO, Bender H, Gulhke S, Marek MJ, Knapp FF Jr, Rhodes BA, et al. Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Anticancer Res 1997; 17:1803 - 1808
   PubMed Web of Science ®Google Scholar
• Gestin JF, Loussouarn A, Bardies M, Gautherot E, Gruaz-Guyon A, Saï-Maurel C, et al. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J Nucl Med 2001; 42:146 - 153
   PubMed Web of Science ®Google Scholar
• Karacay H, McBride WJ, Griffiths GL, Sharkey RM, Barbet J, Hansen HJ, et al. Experimental pretargeting studies of cancer with a humanized anti-CEA × murine anti-[In-DTPA] bispecific antibody construct and a 99mTc-/188Re-labeled peptide. Bioconjug Chem 2000; 11:842 - 854
   PubMed Web of Science ®Google Scholar
• van Schaijk FG, Oosterwijk E, Soede AC, Oyen WJ, McBride WJ, Griffiths GL, et al. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: 111In, 131I, 99mTc and 188Re. Clin Cancer Res 2003; 9:3880 - 3885
   Google Scholar
• He J, Liu G, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug Chem 2007; 18:983 - 988
   PubMed Web of Science ®Google Scholar
• Liu G, Dou S, He J, Yin D, Gupta S, Zhang S, et al. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity. Appl Radiat Isot 2006; 64:971 - 978
   PubMed Web of Science ®Google Scholar
• Liu G, Hnatowich DJ. A semiempirical model of tumor pretargeting. Bioconjug Chem 2008; 19:2095 - 2104
   PubMed Web of Science ®Google Scholar
• Lubic SP, Goodwin DA, Meares CF, Song C, Osen M, Hays M. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma. J Nucl Med 2001; 42:670 - 678
   PubMed Web of Science ®Google Scholar
• Liu G, Dou S, Liang M, Chen X, Rusckowski M, Hnatowich DJ. The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size. Eur J Cancer 2009; 45:3098 - 3103
   PubMed Web of Science ®Google Scholar
• Moshakis V, McIlhinney RAJ, Raghaven D, Neville AM. Localization of human tumour xenografts after i.v. administration of radiolabelled monoclonal antibodies. Br J Cancer 1981; 44:91 - 99
   PubMed Web of Science ®Google Scholar
• Siegel JA, Pawlyk DA, Lee RE, Sharkey RM, Horowitz J, Goldenberg DM. Tumor, red marrow and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50:1039 - 1042
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 2003; 9:3897 - 3913
   PubMed Web of Science ®Google Scholar
• Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging 2007; 34:237 - 246
   PubMed Web of Science ®Google Scholar
• Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. Further investigations of morpholino pretargeting in mice-establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging 2005; 32:1115 - 1123
   PubMed Web of Science ®Google Scholar